New combo aims to tackle myeloma and kidney failure at once

NCT ID NCT06142396

Recruiting now Disease control Sponsor: Augusta University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 30 people newly diagnosed with multiple myeloma who also have kidney failure. The goal is to see if the treatment can shrink the cancer and improve kidney function. Researchers will also compare how well African American and non-African American patients respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab-hyaluronidase combined with bortezomib, cyclophosphamide, and dexamethasone (Dara-CyBorD)
What this could lead to: If successful, this combination could offer a new treatment option for multiple myeloma patients with kidney failure, potentially improving both cancer control and kidney function.
What could go wrong: This is a very early (Phase 1) pilot study with only 30 participants, so results may not apply broadly. The drug combination may cause side effects and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA RENAL FAILURE

Contacts and locations

Locations

Georgia Cancer Center-Augusta University
RECRUITING

Augusta, Georgia, 30912, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.